The notices it replaced
- Reissues: PAR-18-762 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
- 2 steps back: PAR-15-070 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)
Replaced by PAR-25-059.
Who won it before
34 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $13,132,796 in first-year total cost, median $391,745.
Most frequent study sections
- Neurological Sciences and Disorders B Study Section[NSD-B]18
- Neurological Sciences and Disorders A Study Section[NSD-A]15
- Neurological Sciences and Disorders C Study Section[NSD-C]1
Most frequent institutions
- DUKE UNIVERSITY2
- JOHNS HOPKINS UNIVERSITY2
- MASSACHUSETTS GENERAL HOSPITAL2
- MAYO CLINIC ROCHESTER2
- SCRIPPS FLORIDA2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Development of therapeutics for SCA481R61NS138384-01A1 | SCAGLIONE, KENNETH MATTHEW | DUKE UNIVERSITY, NC | $392,863 | NSD |
| 2025 | Optimized Anti-Epileptic Screening Using Drosophila Models1R61NS134960-01A1 | REITER, LAWRENCE T | TULANE UNIVERSITY OF LOUISIANA, LA | $363,602 | NSD |
| 2025 | High-throughput small molecule screen to reduce endogenous level of Msh3 for disease-modifying HD therapy1R61NS140733-01 | YANG, XIANGDONG WILLIAM | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $345,114 | NSD |
| 2024 | OPC-X screen: Discovery of small molecule inhibitors to overcome extrinsic inhibition of remyelination.1R61NS133257-01A1 | AKASSOGLOU, KATERINA | J. DAVID GLADSTONE INSTITUTES, CA | $458,325 | NSD |
| 2024 | Development and validation of a high throughput screening assay for identification of tau aggregation inhibitors in Alzheimer's disease1R61NS136666-01 | SOTO, CLAUDIO | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $371,919 | NSD |
| 2024 | Screening for Nuclear Receptor TLX ligands1R61NS133955-01A1 | BURRIS, THOMAS P | UNIVERSITY OF FLORIDA, FL | $323,079 | NSD |
| 2023 | Development of a phenotypic screening assay for novel compounds that inhibit peripheral pain-sensing neurons1R61AT012117-01A1 | CLARKE, WILLIAM P | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $437,991 | NSD |
| 2023 | In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastoma1R61NS128071-01A1 | MAHER, LOUIS JAMESSARKARIA, JANN N. | MAYO CLINIC ROCHESTER, MN | $414,690 | NSD |
| 2023 | Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors1R61NS133080-01 | ODOM, GUY LEARY | UNIVERSITY OF WASHINGTON, WA | $411,074 | NSD |
| 2023 | High content analgesic screening from human nociceptors1R61AT011938-01A1 | DUSSOR, GREGORY OKOLBER, BENEDICT JPANCRAZIO, JOSEPH J. | UNIVERSITY OF TEXAS DALLAS, TX | $370,187 | NSD |
| 2023 | Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain1R61AT012544-01 | GOLDSTEIN, STEVE A NZHAO, RUIMING | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $256,401 | NSD |
| 2022 | Optimizing Small Molecule Read-Through Compounds for Treating AtaxiaTelangiectasia1R61NS119708-01A1 | MATHEWS, PAUL JAMES | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $508,727 | NSD |
| 2022 | Identifying compounds that target APOE4 associated brain endothelial dysfunction1R61NS124970-01 · under PAR-18-762 | TAI, LEON MAING | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $358,909 | NSD |
| 2022 | Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma1R61NS121386-01A1 · under PAR-18-762 | KAMENECKA, THEODORE MMILLER, COURTNEY ARUMBAUGH, GAVIN RSCAMPAVIA, LOUIS DANIELSPICER, TIMOTHY PATRICKSWEENEY, H LEE | SCRIPPS FLORIDA, FL | $185,371 | NSD |
| 2021 | Deve inlopment of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation1R61NS114147-01A1 · under PAR-18-762 | DANIELS, DAVID | MAYO CLINIC ROCHESTER, MN | $899,750 | NSD |
| 2021 | High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitors1R61NS119659-01 · under PAR-18-762 | SLUSHER, BARBARA STAUCHTSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $409,354 | NSD |
| 2021 | Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 21R61NS119658-01 · under PAR-18-762 | KISSIL, JOSEPH | SCRIPPS FLORIDA, FL | $57,529 | NSD |
| 2020 | HTS to identify compounds that increase NAD+ levels in neurons and muscle cells1R61NS111375-01A1 · under PAR-18-762 | BAUR, JOSEPH A.HURYN, DONNA MKHURANA, TEJVIR S | UNIVERSITY OF PENNSYLVANIA, PA | $575,548 | NSD |
| 2020 | Screening for DNA damage response modulators in glioblastoma stem cells1R61NS117554-01 · under PAR-18-762 | BADR, CHRISTIAN ELIASTANNOUS, BAKHOS A | MASSACHUSETTS GENERAL HOSPITAL, MA | $420,000 | NSD |
| 2020 | Development of cellular HTS for 20S proteasome enhancers1R61NS111347-01A1 · under PAR-18-762 | LISABETH, ERIKA MATHESNEUBIG, RICHARD RTEPE, JETZE J. | MICHIGAN STATE UNIVERSITY, MI | $355,857 | NSD |
| 2019 | High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)1R61NS110960-01 · under PAR-18-762 | ROSSOLL, WILFRIED | MAYO CLINIC JACKSONVILLE, FL | $453,500 | NSD |
| 2019 | GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy1R21NS104454-01A1 · under PAR-15-070 | KASAHARA, NORIYUKI | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $401,456 | NSD |
| 2019 | Non-opioids for inflammatory pain: Adenylyl cyclase 1 as a novel target1R61NS111070-01 · under PAR-18-762 | ROMAN, DAVID L.WATTS, VAL J | UNIVERSITY OF IOWA, IA | $400,720 | NSD |
| 2019 | Drug discovery for spinocerebellar ataxia, using novel fluorescence technology targeting β-III-spectrin1R61NS111075-01 · under PAR-18-762 | HAYS, THOMAS S | UNIVERSITY OF MINNESOTA, MN | $383,926 | NSD |
| 2019 | Slack Potassium Channel Inhibitors for the Treatment of Childhood Epilepsies1R21NS109521-01 · under PAR-15-070 | EMMITTE, KYLE AWEAVER, C DAVID | VANDERBILT UNIVERSITY, TN | $290,733 | NSD |
| 2018 | Immortalized Striatal Precursor Neurons as a Screenable Model of HD1R21NS104320-01A1 · under PAR-15-070 | ROSS, CHRISTOPHER A | JOHNS HOPKINS UNIVERSITY, MD | $403,537 | NSD |
| 2018 | High-content screening for modulators of lamin B1 as a therapeutic target in autosomal dominant leukodystrophy1R21NS106087-01 · under PAR-15-070 | PADIATH, QUASAR SVOGT, ANDREAS | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $390,626 | NSD |
| 2018 | Small molecule stabilizers of Hsp70 for treatment of spinal and bulbar muscular atrophy1R21NS101030-01A1 · under PAR-15-070 | LIEBERMAN, ANDREW POSAWA, YOICHI | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $388,542 | NSD |
| 2018 | Development of SK channel modulators as therapeutic agents for ataxia1R21NS101182-01A1 · under PAR-15-070 | BEZPROZVANNY, ILYA BZHANG, MIAO | CHAPMAN UNIVERSITY, CA | $186,750 | NSD |
| 2017 | Developing Novel RNA-Based Therapeutics for Parkinson's Disease1R21NS096032-01A1 · under PAR-15-070 | DISNEY, MATTHEW DMOURADIAN, M. MARAL | RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL, NJ | $452,438 | NSD |
| 2017 | Anticonvulsant screening using chronic epilepsy models1R21NS096948-01A1 · under PAR-15-070 | BERDICHEVSKY, YEVGENYDUDEK, F. EDWARDDULLA, CHRIS GSTALEY, KEVIN J. | MASSACHUSETTS GENERAL HOSPITAL, MA | $443,878 | NSD |
| 2017 | Discovery of Post-transcriptional utrophin upregulator small molecules for Duchenne Muscular Dystrophy therapeutics1R21NS102838-01 · under PAR-15-070 | KHURANA, TEJVIR S | UNIVERSITY OF PENNSYLVANIA, PA | $402,500 | NSD |
| 2017 | Allele-specific RNA-targeted lead compounds for Huntington's disease1R21NS099516-01A1 · under PAR-15-070 | WARNER, KATHERINE DEIGAN | RIBOMETRIX, LLC, NC | $260,150 | NSD |
| 2016 | Inhibitors of TrkB Signaling1R21NS094863-01 · under PAR-15-070 | MCNAMARA, JAMES O. | DUKE UNIVERSITY, NC | $357,750 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.